



Tourette Syndrome: A Case Study of a 25-Year-Old Male

¹**Arshita Matta**, M.A. *Clinical Psychology Student, Amity Institute of Psychology and Allied Sciences, Amity University, Noida*

arshita.matta@gmail.com

²**Dr. Roopali Sharma**, *Professor, Amity Institute of Psychology and Allied Sciences, Amity University, Noida*

rsharma13@amity.edu

Abstract: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple motor and at least one vocal tic persisting for over a year. This case study examines a 25-year-old male, Mr. Y, whose symptoms began at age 12 with eye blinking and progressed to include neck jerking, shoulder jerking, and mild vocal disruptions. His family history revealed a genetic predisposition, with milder tic symptoms present in his father and grandfather. Neurological evaluations ruled out structural abnormalities, and a comprehensive therapeutic approach was implemented, combining pharmacological treatment with behavioral interventions such as Habit Reversal Therapy (HRT), cognitive awareness training, and relaxation techniques. The study highlights the waxing and waning nature of tics, their exacerbation under stress, and the importance of individualized management strategies. The findings align with existing literature on TS, emphasizing the roles of genetic factors, neurobiological dysfunctions, and evidence-based therapies in improving quality of life for individuals with TS.

Keywords: *Tourette syndrome, neurodevelopmental disorders, Habit Reversal Therapy, behavioural interventions, genetic predisposition.*

1. Introduction

Multiple motor and one or more verbal tics that last longer than a year are the features of Tourette syndrome (TS), a neurodevelopmental condition (American Psychiatric Association [APA], 2022). Tics are abrupt, fast, repetitive, nonrhythmic vocalizations or movements that can change in frequency and intensity over time. According to Robertson (2015), the illness usually first appears in childhood, peaks in adolescence, and occasionally lasts into maturity. Although the precise etiology is still unknown, TS is thought to be caused by a complex interaction between environmental and genetic factors, with evidence pointing to a significant hereditary component (Mataix-Cols et al., 2015).

According to various research, the prevalence of TS fluctuates between 0.3% and 1% of the world's population, with males experiencing a higher frequency than females at a ratio of roughly 4:1 (Robertson, 2019). According to research, TS frequently coexists with other neuropsychiatric diseases, including anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and obsessive-compulsive disorder (OCD), which makes its clinical presentation extremely complex (Hirschtritt et al., 2015).

According to Wang et al. (2018), TS is linked to neurobiological dysfunctions in the cortico-striato-thalamo-cortical circuits, which are important in behavioral regulation and motor control. Changes in the basal ganglia, namely in the caudate nucleus, which is essential for movement regulation, have been brought to light by structural and functional imaging investigations (Martino et al., 2017). Furthermore, the pathophysiology of TS has been linked to dysregulation of neurotransmitters like dopamine and gamma-aminobutyric acid (GABA) (Ganos et al., 2018).

This case report describes the clinical profile of a 25-year-old male diagnosed with Tourette syndrome, including his medical history, symptomatology, neurological examinations, and indicated therapeutic approaches for management. By investigating this instance, the study hopes to add to the expanding body of literature on TS and its clinical consequences in adults, highlighting the need of early detection and tailored treatment approaches.

2. Case Presentation

2.1 Demographic and Developmental History

Mr. Y, a male 25-year-old, is his parents' eldest kid. There were no reported delivery problems, and he was born at full term with a typical birth scream. Between the ages of six months and one year, he fell off the bed twice, according to the informant, his mother. At the

age of nine or ten, he also experienced a high fever and a rigid physique. At the time, the parents sought medical attention from a private physician, and the suggested meds helped to alleviate the symptoms.

To comprehend neurodevelopmental disorders such as Tourette syndrome (TS), developmental history is essential. Even though Mr. Y's case did not involve any direct prenatal difficulties, early childhood falls, and feverish illnesses have been studied as possible causes of neurological vulnerabilities (Mathews et al., 2014). Although more research is needed to demonstrate a clear causal linkage, studies suggest that tic disorders may be related to immune system responses and infections in early childhood (Hoekstra et al., 2013).

2.2 Family History and Genetic Considerations

There has been evidence of a genetic component to tic disorders (Eapen et al., 2016). A potential genetic tendency is suggested by the moderate eye twitching that Mr. Y's father and grandfather also had. Nonetheless, Mr. Y's symptoms are more severe than his father's in comparison. In order to rule out other possible explanations, the family sought neurological evaluation due to this inherited pattern.

Genetic studies have identified several susceptibility loci for TS, including those related to brain development and dopamine signalling (Paschou, 2013). According to twin studies, TS has a 50–77% heritability, highlighting its significant genetic influence (Davis et al., 2013). Additionally, risk SNPs linked to neurodevelopmental processes and synapse function have been revealed by genome-wide association studies (Yu et al., 2019). It is in line with established hereditary patterns of TS inheritance that Mr. Y's family has had tic symptoms for many generations.

2.3 Symptom Onset and Progression

Mr. Y's tic-like actions began around the age of 12. At the time, the family observed frequent eye blinking, but the symptoms were not severe enough to cause substantial concern or impairment in everyday functioning. The symptoms intensified with time and are now more frequent and annoying for him.

The tics currently experienced by the client include:

- ***Motor tics***: Eye blinking, neck jerking, shoulder jerking
- ***Vocal tics***: Mild disruptions in speech (slight vocal issues)

Tics in TS often have a waxing and waning pattern, which means that their intensity and frequency might change over time (Bloch & Leckman, 2009). Many people say that their tics worsen during times of stress, anxiety, or exhaustion (Conelea & Woods, 2008). In Mr. Y's

instance, he has become self-aware of his tics and actively works to regulate them in social settings. For example, while eating, he anticipates a tic and bends down to reduce the likelihood of spilling food. This level of cognitive control demonstrates his purposeful effort to reduce the influence of tics in daily activities.

2.4 Neurological Evaluation and Medical Management

Concerned about the severity of the symptoms, the family requested a neurological evaluation. According to the information provided by the informant, Mr. Y's neurological examinations yielded normal results, ruling out structural or pathological problems in his brain. Despite this, the recurrence and severity of symptoms prompted a mental referral, and a tentative diagnosis of Tourette syndrome was given.

Mr. Y also mentioned having strong migraines accompanied by watery eyes and occasional vomiting. Migraine has been identified as a concomitant disease in some cases with tic disorders (Ganos et al., 2017), emphasizing the complexities of his clinical picture.

2.5 Therapeutic Interventions

Following his diagnosis, Mr. Y was referred to the Behavioral Therapy Unit for additional treatment. Given that Tourette syndrome (TS) is best handled with a combination of pharmaceutical and behavioral techniques, Mr. Y received a structured therapeutic plan to assist him gain control of his tics and enhance his quality of life. The psychological strategy for treating his tics includes:

1. ***Continuation of Medication:*** The client was encouraged to follow the neurologist's indicated pharmacological treatment for effective tic management. While drugs can help lessen the severity of tics, their effectiveness varies by individual, and side effects must be monitored (Roessner et al., 2011). Regular follow-ups with a healthcare professional were advised to check the effectiveness of medicine and alter dosages as necessary.
2. ***Habit Reversal Therapy (HRT):*** It is a popular behavioral intervention for tics that trains individuals to establish a competing response to replace tic behaviors (Piacentini et al., 2010). The psychologist intended to work with Mr. Y to identify other physical gestures that may be used in place of tics. For example, in reaction to neck jerks, the client could be taught to perform a purposeful counter-movement that reduces tic frequency over time. HRT has been demonstrated to be quite successful in reducing tics, especially when used regularly over time (McGuire et al., 2014).
3. ***Cognitive Awareness Training:*** Enhancing self-awareness of tic triggers and patterns can aid in effective management. The client was encouraged to identify high-risk

circumstances when tics worsened (e.g., social gatherings, stressful environments), monitor and manage one tic at a time, and progressively develop control over involuntary movements. Use cognitive-behavioral strategies to confront negative ideas connected with his tics, thereby reducing anxiety-driven exacerbations.

4. ***Relaxation Techniques:*** Stress and worry can increase tics (Conelea & Woods, 2008). The client was recommended to adopt deep breathing, progressive muscular relaxation, and mindfulness practices into his everyday routine. This method attempts to lessen the frequency of tics by maintaining a calm physiological state. According to research, relaxation-based therapies can be beneficial in treating stress-induced tic exacerbation, making them an important complementary strategy (Specht et al., 2022).

3. Discussion

The example of Mr. Y is consistent with existing literature on the typical course and treatment of Tourette syndrome (TS). As seen in this case, TS frequently appears in childhood, with symptoms peaking throughout puberty and extending into maturity in some people (Robertson, 2015). The hereditary pattern observed in Mr. Y's family adds to evidence demonstrating a high genetic component in TS, with studies predicting heritability rates ranging from 50-77% (Davis et al., 2013). The treatment interventions advised in this case are based on empirical research. Habit reversal therapy has been identified as an effective non-pharmacological strategy to tic reduction (Piacentini et al., 2010), with relaxation techniques serving as a supplement to manage stress-related tic exacerbation (Conelea & Woods, 2008).

Mr. Y's tic symptoms progressed from little, intermittent eye blinking at age 12 to more sophisticated physical and vocal tics in adulthood. The waxing and waning form of tics is congruent with known TS patterns (Bloch & Leckman, 2009). His self-awareness and adaptive behaviors, such as adjusting his posture while eating to avoid spills, indicate an effort to manage symptoms in social settings, which is consistent with research showing that some adults with TS develop compensatory strategies to reduce tic-related disruption (Ganos et al., 2012).

Mr. Y's co-occurring migraine episodes are notable, given studies indicate an increased occurrence of migraine in people with TS. While the specific link is unknown, both disorders are thought to have underlying neurobiological processes, such as dopaminergic dysfunction and sensory hypersensitivity (Ganos et al., 2017). This emphasizes the importance of a comprehensive approach in treatment TS and its symptoms.

The behavioral therapies offered to Mr. Y, such as Habit Reversal Therapy (HRT) and relaxation techniques, are supported by substantial empirical data. HRT is widely regarded as an effective non-pharmacological strategy to tic reduction, especially when used regularly over time (McGuire et al., 2014). Furthermore, mindfulness-based methods have been shown to help minimize stress-induced tic aggravation, suggesting their inclusion in TS treatment programs (Specht et al., 2022).

Mr. Y's case demonstrates the complexities of TS management and the value of a personalised treatment approach. While pharmaceutical treatments remain an important part of tic management, their efficacy varies, necessitating alternative or supplementary therapies such as cognitive-behavioral therapy and relaxation training (Roessner et al., 2011). Future research should focus on the genetic, neurological, and behavioral aspects that influence tic intensity and treatment response, with the goal of developing more customized and successful therapies.

4. Conclusion

This case study examines the clinical history of Tourette syndrome (TS) in a 25-year-old man, focusing on the role of genetic risk, symptom progression, and therapeutic therapy. Mr. Y's example is consistent with previous data, which shows a steady deterioration of tics from childhood to adulthood, a pattern typically seen in people with TS. The presence of a hereditary component in his family history lends credence to research indicating that TS has a strong genetic base, with dopaminergic and neurodevelopmental variables playing important roles.

A comprehensive strategy was required to manage Mr. Y's problems. While pharmacological treatment was beneficial, it was augmented with behavioral strategies such as Habit Reversal Therapy (HRT), cognitive awareness training, and relaxation techniques—all of which have been empirically validated for tic management. Furthermore, his migraine episodes demonstrate the importance of a comprehensive treatment approach that tackles both main tic symptoms and underlying related problems.

While Tourette syndrome is still a difficult illness to manage, early intervention, structured therapeutic tactics, and individualized treatment programs can dramatically improve quality of life. Future study should look at genetic, neurological, and environmental factors that influence TS progression and treatment response, which will lead to more tailored and effective interventions and a higher quality of life.

References

American Psychiatric Association (APA). (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.). American Psychiatric Association Publishing.

- Bloch, M. H., & Leckman, J. F. (2009). Clinical course of Tourette syndrome. *Journal of Psychosomatic Research*, 67(6), 497–501.
- Conelea, C. A., & Woods, D. W. (2008). The influence of contextual factors on tic expression in Tourette's syndrome: A review. *Journal of Psychosomatic Research*, 65(5), 487–496.
- Davis, L. K., Yu, D., Keenan, C. L., Gamazon, E. R., Konkashbaev, A., Derks, E. M., & Scharf, J. M. (2013). Partitioning the heritability of Tourette syndrome and obsessive-compulsive disorder reveals differences in genetic architecture. *PLoS Genetics*, 9(10).
- Eapen, V., Črnčec, R., & Robertson, M. M. (2016). Comorbidities, social impact, and quality of life in Tourette syndrome. *Frontiers in Psychiatry*, 7, 97.
- Eapen, V., Španiel, F., Štěpánková, H., & Mathews, C. A. (2016). Genetic influences in Tourette syndrome. *The Psychiatric Clinics of North America*, 39(4), 601-609.
- Ganos, C., Martino, D., & Pringsheim, T. (2018). Pathophysiology of tics: Current status and future directions. *Movement Disorders Clinical Practice*, 5(2), 117-129.
- Ganos, C., Roessner, V., & Müller-Vahl, K. (2012). Understanding tic disorders: Clinical aspects and management. *Journal of Neural Transmission*, 119(5), 531–546.
- Ganos, C., Roessner, V., & Münchau, A. (2017). The functional anatomy of Gilles de la Tourette syndrome. *Neuroscience & Biobehavioral Reviews*, 37(6), 1050-1062.
- Hartmann, A., & Worbe, Y. (2018). Pharmacological treatment of Tourette syndrome. *Neuroscience & Biobehavioral Reviews*, 86, 137–142.
- Hirschtritt, M. E., Lee, P. C., Pauls, D. L., Dion, Y., King, R. A., Osiecki, L., McMahon, W. M., & Mathews, C. A. (2015). Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. *JAMA Psychiatry*, 72(4), 325-333.
- Martino, D., Ganos, C., & Pringsheim, T. M. (2017). Tourette syndrome and dystonia: Pathophysiological and clinical considerations. *Progress in Neurobiology*, 159, 132-142.
- Martino, D., Johnson, I., & Leckman, J. F. (2017). Neuroimaging in Tourette syndrome. *NeuroImage: Clinical*, 15, 806–818.
- Mataix-Cols, D., Isomura, K., Pérez-Vigil, A., Fan, Q., Kuja-Halkola, R., & Larsson, H. (2015). Familial risks of Tourette syndrome and chronic tic disorders: A population-based cohort study. *Lancet Psychiatry*, 2(6), 528-534.

- McGuire, J. F., Piacentini, J., Woods, D. W., Scahill, L., Wilhelm, S., Peterson, A. L., & Walkup, J. T. (2014). A randomized controlled trial of behavior therapy for Tourette's disorder. *JAMA Psychiatry*, 71(9), 981–989.
- Piacentini, J., Woods, D. W., Scahill, L., Wilhelm, S., Peterson, A. L., Chang, S., & Walkup, J. T. (2010). Behavior therapy for children with Tourette disorder. *Journal of the American Medical Association*, 303(19), 1929-1937.
- Robertson, M. M. (2015). A personal 35-year perspective on Gilles de la Tourette syndrome: Prevalence, phenomenology, comorbidities, and coexistent psychopathologies. *The Lancet Psychiatry*, 2(1), 68–87.
- Robertson, M. M. (2019). The prevalence and epidemiology of Gilles de la Tourette syndrome: Part 1—The epidemiological and prevalence studies. *Journal of Neuropsychiatry and Clinical Neurosciences*, 31(2), 103-110.
- Roessner, V., Eichele, H., Stern, J. S., & Skov, L. (2011). Pharmacological treatment of tic disorders and Tourette syndrome. *Neuropharmacology*, 62(2), 879–891.
- Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., & Skov, L. (2011). European clinical guidelines for Tourette syndrome and other tic disorders. *European Child & Adolescent Psychiatry*, 20(4), 173-196.
- Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B., & Jankovic, J. (2001). Contemporary assessment and pharmacotherapy of Tourette syndrome. *NeuroRx*, 1(2), 192–206.
- Specht, M. W., Woods, D. W., & Piacentini, J. (2022). Mindfulness-based interventions for tic disorders: A review of current evidence. *Clinical Psychology Review*, 92, 102108.
- Verdellen, C., van de Griendt, J., Hartmann, A., & Murphy, T. (2011). European clinical guidelines for Tourette syndrome and other tic disorders: Treatment. *European Child & Adolescent Psychiatry*, 20(4), 173–196.
- Wang, Z., Maia, T. V., Marsh, R., Colibazzi, T., Gerber, A., & Peterson, B. S. (2018). The neural circuits that generate tics in Tourette's syndrome. *American Journal of Psychiatry*, 175(6), 573–585.
- Yu, D., Sul, J. H., Tsetsos, F., Nawaz, M. S., Huang, A. Y., Zelaya, I., & Mathews, C. A. (2019). Interrogating the genetic determinants of Tourette syndrome and other tic disorders through genome-wide association studies. *American Journal of Psychiatry*, 176(3), 217–227.